ArticlePatient preference and adherence2023

Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia.

Xiaoxiao Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.